Thalidomide and its analogues in the treatment of Multiple Myeloma
1 UC Cancer Institute, Division of Hematology-Oncology, University of Cincinnati School of Medicine, Cincinnati, OH, USA
2 Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR, USA
3 Carolyn & Neag Comprehensive Cancer Center, Lea’s Center for Hematologic Disorders, University of Connecticut Health Center, Farmington, CT, USA
Experimental Hematology & Oncology 2012, 1:27 doi:10.1186/2162-3619-1-27Published: 11 September 2012
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.